drugset / Trial / NCT03059173

Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome

NCT03059173

RandomizedParallel-groupTriple-blindTreatment

Summary

The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.

Timeline

Start
2023-09-12
Primary completion
2027-09-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Background Clomiphene Other / unclassified 50 mg